We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+33.73%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.59B
AUM Growth
+$475M
Cap. Flow
-$61.5M
Cap. Flow %
-2.37%
Top 10 Hldgs %
31.64%
Holding
140
New
7
Increased
46
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$23.1M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$16.6M
3
CI icon
Cigna
CI
+$16.4M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$15M
5
TVTX icon
Travere Therapeutics
TVTX
+$9.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$44.7M
2
LOXO
Loxo Oncology, Inc
LOXO
+$33.8M
3
MOH icon
Molina Healthcare
MOH
+$18.2M
4
WCG
Wellcare Health Plans, Inc.
WCG
+$18M
5
BIIB icon
Biogen
BIIB
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Miscellaneous 1.82%
3 Consumer Staples 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WMGI
26
DELISTED
Wright Medical Group Inc
WMGI
$29M 1.12%
920,608
-79,392
-8% -$2.41M
ONC
27
BeOne Medicines Ltd
ONC
$39.2B
$28.4M 1.09%
214,800
– –
ACHC icon
28
Acadia Healthcare
ACHC
$2.63B
$27.1M 1.05%
925,000
+24,250
+3% +$687K
NVTA
29
DELISTED
Invitae Corporation
NVTA
$26.9M 1.04%
1,150,000
-250,000
-18% -$4.41M
IDXX icon
30
Idexx Laboratories
IDXX
$40.9B
$26.9M 1.04%
120,200
+9,700
+9% +$2M
INCY icon
31
Incyte
INCY
$25B
$26.9M 1.04%
312,300
+2,300
+0.7% +$187K
PRAH
32
DELISTED
PRA Health Sciences, Inc.
PRAH
$26.5M 1.02%
240,000
+40,000
+20% +$4.18M
ASND icon
33
Ascendis Pharma A/S
ASND
$16.2B
$25.1M 0.97%
213,500
-30,000
-12% -$2.63M
INSM icon
34
Insmed
INSM
$26.9B
$24.7M 0.95%
850,000
– –
BAX icon
35
Baxter International
BAX
$12.1B
$24.4M 0.94%
300,700
– –
COLL icon
36
Collegium Pharmaceutical
COLL
$720M
$23.9M 0.92%
1,577,893
-27,212
-2% -$436K
RDUS
37
DELISTED
Radius Health, Inc.
RDUS
$23.4M 0.9%
1,175,000
+75,000
+7% +$1.37M
BIIB icon
38
CALL
Biogen
BIIB
$32.2B
$23M 0.89%
+97,500
New +$30.7M
ARGX icon
39
argenx
ARGX
$61.5B
$22.7M 0.87%
181,700
+3,700
+2% +$435K
TMO icon
40
Thermo Fisher Scientific
TMO
$239B
$22.2M 0.85%
81,000
-15,000
-16% -$3.73M
BPMC
41
DELISTED
Blueprint Medicines
BPMC
$22M 0.85%
275,000
+61,342
+29% +$4.53M
ALNY icon
42
Alnylam Pharmaceuticals
ALNY
$32.2B
$21.8M 0.84%
233,500
+39,500
+20% +$3.3M
EPZM
43
DELISTED
Epizyme, Inc
EPZM
$21.7M 0.84%
1,753,375
+145,875
+9% +$1.63M
ALDR
44
DELISTED
Alder Biopharmaceuticals
ALDR
$21.3M 0.82%
1,560,000
+85,000
+6% +$1.1M
CVET
45
DELISTED
Covetrus, Inc. Common Stock
CVET
$20.7M 0.8%
+650,000
New +$23.1M
BOLD
46
DELISTED
Audentes Therapeutics, Inc
BOLD
$20.4M 0.79%
522,500
+22,500
+5% +$645K
MDCO
47
DELISTED
Medicines Co
MDCO
$20.4M 0.79%
729,400
+2,500
+0.3% +$58.9K
LKFT
48
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$19.4M 0.75%
165,000
-12,500
-7% -$1.26M
TVTX icon
49
Travere Therapeutics
TVTX
$6B
$18.8M 0.72%
830,000
+430,000
+108% +$9.5M
RARX
50
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$18M 0.69%
804,000
+54,000
+7% +$1.16M
1
2
3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rock Springs Capital Management held 140 positions worth $2.59B, up 22% from $2.12B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rock Springs Capital Management's Q1 2019 filing shows 7 new, 46 increased, 13 reduced and 9 closed positions. Its largest new stake was Covetrus, Inc. Common Stock: 650,000 shares worth $20.7M. The largest sale was TESARO, Inc., an estimated $44.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Rock Springs Capital Management's largest Q1 2019 buy was Covetrus, Inc. Common Stock: 650,000 shares worth $20.7M.
  • Rock Springs Capital Management added most to Portola Pharmaceuticals, Inc. in Q1 2019, an estimated $16.6M increase.
  • Rock Springs Capital Management's biggest Q1 2019 reduction was Molina Healthcare, cutting an estimated $18.2M.
  • Rock Springs Capital Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $44.7M.
  • Rock Springs Capital Management's ten largest holdings make up 32% of its $2.59B portfolio in Q1 2019.
  • Rock Springs Capital Management opened 7 new positions and closed 9 in Q1 2019.
  • Rock Springs Capital Management's portfolio value rose 22% quarter-over-quarter to $2.59B.

Based on Rock Springs Capital Management's 13F filing for Q1 2019, filed 15 May 2019.